Freenome Ltd is a leading immunodiagnostics developer, primarily focused on the growing field of diagnostic products to detect early-stage cancer.​

Freenome Ltd’s immunodiagnostic technology, EarlyCDT, can detect and help identify cancer on average four years earlier than standard clinical diagnosis.

Freenome Ltd has a commercialized CE-IVD marked lung test that has impacted the clinical journey of more than 200,000 patients at a high risk of lung cancer and those with indeterminate pulmonary nodules (IPN).

Their platforms, products, and clinical research have been featured in more than 150 presentations, posters, keynotes, and peer-reviewed publications.